PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research3 citations

Neoadjuvant Niraparib with Dostarlimab in BRCA or PALB2-Mutated Breast Cancer

Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

View Full Paper

Authors

EME. L. MayerNGNoah GrahamRLR. A. Leon-Ferre

Discussion

Loading...

Member takes

Overview

Phase 2 study evaluates pCR in patients with BRCA- or PALB2-mutated breast cancer, suggesting effective immunotherapy combinations.

Key Points

  • The study aims to evaluate the efficacy of neoadjuvant niraparib and dostarlimab in achieving pathologic complete response in patients with BRCA- or PALB2-mutated breast cancer.
  • Performed a phase II randomized trial with two treatment arms: combination therapy versus monotherapy.
  • Enrolled 46 patients with early-stage triple-negative breast cancer (TNBC).
  • Conducted tumor biopsies at baseline and week 3 to evaluate stromal tumor infiltrating lymphocytes (sTILs).
  • Assessed pathologic complete response (pCR) rates after 18 weeks of treatment.
  • Achieved a pathologic complete response (pCR) rate of 50% among enrolled participants.
  • Significant increases in sTILs from baseline to week 3 were observed in both arms.
  • No relationship was found between pCR rates and baseline PD-L1 scores or ER status.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mayer et al. (2026) studied this question.

synapsesocial.com/papers/6996a869ecb39a600b3ef210https://doi.org/10.1158/1557-3265.sabcs25-rf5-02
Ask AI
Helpful
Bookmark
Share
View Full Paper